MGI Tech Co., Ltd. announced the collaboration with Predica Diagnostics B.V to develop Predica's targeted RNA sequencing tests on the cost-effective MGI Next-generation sequencing platforms. The collaboration seeks to revolutionize molecular diagnost ics by enabling early cancer detection and facilitating personalized targeted treatment strategies. By combining Predica Diagnostics' advanced sequencing assays with MGI's Next-generation sequencing platforms, the initiative promises a rapid, accurate, and affordable solution for healthcare providers. Predica Diagnostics, renowned for its expertise in cervical cancer screening through its proprietary ciRNAseq-based test, CervicaDx, brings unparalleled precision in identifying high-risk HPV oncogenes and other (pre)malignancy biomarkers.

By integrating this advanced diagnostic capability with MGI's robust and affordable DNBSEQ technology, the partnership aims to significantly enhance the accuracy and accessibility of diagnostic tests. A core value of this partnership is making high-quality diagnostic and predictive testing more affordable and accessible. MGI Tech's DNBSEQ platforms, recognized for their cost-efficiency and scalability, will enable healthcare institutions to offer advanced genomic and transcriptomic testing at a lower cost.

Compared to existing NGS-based technologies, MGI's platform offers cost-effective and faster results. Within the collaboration, MGI's NGS platform will be deployed for conducting the final analysis of Predica's disruptive, ciRNAseq-based targeted RNA sequencing tests. This combination will help researchers and healthcare professionals to better predict patient prognosis and guide treatment with precision medicines.